The company seems to have stumbled upon an opportunity. A big opportunity. It looks to me like they have the IP to expand their operation way past that of refining stevia. Read the 8k recently filed. They now have the intellectual property that is coveted by big pharma to extend drug patent rights. This is a really big deal, people that have been holding STVF are in for a windfall
I got in just under 189 and sold off today just south of 205. This was an easy play for 8% gain with low risk in less than 2 months.
we need a nice earnings surprise and positive forward guidance at the end of the month.
That is pretty much the bottom line. Growth via internal organic or acquisition should pave the future
A lot of profit takers that bought in at the $5 price a few weeks ago selling on news and booking profits. Then stop loss orders kicked in making the dip appear more drastic. It will close much higher than the days low point as people dissect the positive data and realize that this is the second cancer type that immunopulse has shown clinical proof of positive results. Basically the platform works and now can be tested with confidence on several other cancer types.
The exodus of talent from Merck to ONCS makes me think that something big about to happen. These are highly educated executives, researchers, and doctors that are transitioning to ONCS. Seems like people inside the inner circle know that the future is bright.
ONCS looks to be positioning themselves well as the leader in the space. Progress is being made with each and every deal.
good entry point. glad you were able to buy in. i bought at 284 so with the exception of some nice dividend payments i am down a bit...